ALPS Advisors’s Immuneering IMRX Stock Holding History

ALPS Advisors’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$328K	Buy	+65,658	New	+$332K	﹤0.01%	1075

Other funds holding IMRX

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Flower City Capital Pittsford, New York $227M AUM 23.31% 1-Year Est. Return

Berman McAleer Timonium, Maryland $864M AUM 22.02% 1-Year Est. Return

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Nations Financial Group Cedar Rapids, Iowa $2.09B AUM 34.27% 1-Year Est. Return

Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Wendell David Associates Portsmouth, New Hampshire $947M AUM 10.27% 1-Year Est. Return

ALPS Advisors's IMRX Position: Q2 2026 in Review

ALPS Advisors opened a new position in Immuneering (IMRX) in Q2 2026: 65,658 shares worth $328K. The stake represents ﹤0.01% of the portfolio and ranks #1075 among its holdings.

19 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

ALPS Advisors held 65,658 shares of Immuneering worth $328K as of Q2 2026.
Immuneering was a new ALPS Advisors position in Q2 2026.
Immuneering made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #1075 holding.
19 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.